Shaniqua J. Anum, Julie Kanter/ scholars.uab.edu
Aug 23, 2026, 14:10
Intravenous Arginine Fails to Reduce Acute Sickle Cell Pain – JAMA
JAMA shared a post on LinkedIn about a recent article by Shaniqua J. Anum and Julie Kanter, adding:
”Acute pain episodes in Sickle Cell Disease remain a leading cause of emergency department visits and hospitalization, yet treatment still relies largely on opioids, nonsteroidal anti-inflammatory drugs, and intravenous fluids.
The STArT trial of intravenous Arginine found no overall benefit vs placebo, and heterogeneity in acute pain mechanisms and trial end points may have limited detection of a vascular-targeted treatment effect.”
Title: Arginine Treatment and Sickle Cell Disease Pain — A Great STArT, but a Hard End Point
Authors: Shaniqua J. Anum, Julie Kanter
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 1, 2026, 07:52Marc Carrier: TRIM-Line Trial Evaluates VTE Prevention in Cancer
-
Oct 1, 2026, 07:29Ariela Marshall: New Guidelines Provide Updated Recommendations for Iron Deficiency Diagnosis
-
Sep 30, 2026, 22:28Recent Mechanical Risk Factors and Young-Onset Cryptogenic Ischemic Stroke – American Heart Association International
-
Sep 30, 2026, 22:22Expert Consensus on Inferior Vena Cava Thrombosis – Thrombosis and Haemostasis Journal
-
Sep 30, 2026, 22:21Markus Abeln: How Platelets and Complement Shape Placental Blood Flow
-
Sep 30, 2026, 22:19Fatma Al Arbawi: Studying Blood Clot Mechanics to Understand Aspirin Resistance and Thrombosis
-
Sep 30, 2026, 22:17Sudhir Kumar: Stroke is a Medical Emergency – and Every Minute Matters
-
Sep 30, 2026, 22:15Luisa Medeiros Visentini: Our Research on Cognitive Impairment After CVT Cited in the International Journal of Stroke
-
Sep 30, 2026, 21:50Jagat Narula: Connecting Cardiovascular Health and Sickle Cell Disease on World Heart Day 2026